Portal de investigación
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Perez-Lamas, Lucia
- Luna, Alejandro
- Boque, Concepcion
- Xicoy, Blanca
- Giraldo, Pilar
- Perez Lopez, Raul
- Ruiz Nuño C
- de las Heras, Natalia
- Lopez Marin, Javier
- Segura Diaz, Adrian
- Gomez, Valle
- Velez Tenza, Patricia
- Sierra Pacho, Magdalena
- Vera Goñi JA
- Moreno Vega, Melania
- Alvarez-Larran, Alberto
- Cortes, Montse
- Perez Encinas, Manuel
- Carrascosa Mastell, Patricia
- Angona, Anna
- Rosell, Ana
- Lakhwani, Sunil
- Colorado, Mercedes
- Ramila, Elena
- Cervero, Carlos
- Cuevas, Beatriz
- Villalon Blanco, Lucia
- de Paz, Raquel
- Paz Coll, Antonio
- Fernandez, Maria Jose
- Felipe Casado, Luis
- Alonso-Dominguez, Juan Manuel
- Anguita Arance, Maria Magdalena
- Salamanca Cuenca, Araceli
- Jimenez-Velasco, Antonio
- Prendes, Santiago Osorio
- Santaliestra, Marta
- Lis Chulvi, Maria Jose
- Hernandez-Boluda, Juan Carlos
- Garcia-Gutierrez, Valentin
Grupos
Abstract
(1) Background: Despite the prognostic improvements achieved with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), a minority of patients still fail TKIs. The recent introduction of asciminib may be a promising option in intolerant patients, as it is a first-in-class inhibitor with a more selective mechanism of action different from the ATP-competitive inhibition that occurs with TKIs. Therefore, our goal was to analyze toxicities shown with asciminib as well as to study cross-toxicity with previous TKIs. (2) Methods: An observational, multicenter, retrospective study was performed with data from 77 patients with CML with therapeutic failure to second-generation TKIs who received asciminib through a managed-access program (MAP) (3) Results: With a median follow-up of 13.7 months, 22 patients (28.5%) discontinued treatment: 32% (7/22) due to intolerance and 45% (10/22) due to resistance. Fifty-five percent of the patients reported adverse effects (AEs) with asciminib and eighteen percent grade 3-4. Most frequent AEs were: fatigue (18%), thrombocytopenia (17%), anemia (12%), and arthralgias (12%). None of the patients experienced cardiovascular events or occlusive arterial disease. Further, 26%, 25%, and 9% of patients required dose adjustment, temporary suspension, or definitive discontinuation of treatment, respectively. Toxicities under asciminib seemed lower than with prior TKIs for anemia, cardiovascular events, pleural/pericardial effusion, diarrhea, and edema. Cross-toxicity risk was statistically significant for thrombocytopenia, anemia, neutropenia, fatigue, vomiting, and pancreatitis. (4) Conclusion: Asciminib is a molecule with a good safety profile and with a low rate of AEs. However, despite its new mechanism of action, asciminib presents a risk of cross-toxicity with classical TKIs for some AEs.
Datos de la publicación
- ISSN/ISSNe:
- 2072-6694, 2072-6694
- Tipo:
- Article
- Páginas:
- -
- PubMed:
- 36831388
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 1,349 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Cancers MDPI
Citas Recibidas en Web of Science: 27
Documentos
- No hay documentos
Filiaciones
Keywords
- asciminib; chronic myeloid leukemia; drug intolerance; toxicities